Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
 |
The New Vision (Uganda) - September 14, 2001
Charles Wendo
He said this was a preliminary sign that the candidate vaccine might succeed in protecting human beings from HIV infection.
Speaking at the Kampala International Conference Centre during the Global Strategies for the Prevention of Mother-to-Child HIV Transmission conference yesterday, Anzala said they are currently testing the DNA vaccine on a small number of volunteers in Kenya.
The five-day conference ended yesterday.
Anzala said, "After a short time, people who were given the DNA vaccine begun to show a good response."
He, however, said the trial is only in the first phase and there would be a total of four phases in succession.
"It is a long road. It is a difficult road. It takes long to move from one phase to another," he said.
Dr. Pontiano Kaleebu, the lead researcher in the upcoming trial of the vaccine in Uganda, yesterday said in a phone interview with The New Vision that he was happy about the revelation.
"I haven't seen the data myself but people who have seen it say it is exciting. If it is true, that is very good for us," he said.
Kaleebu, an immunologist at the Uganda Virus Research Institute (UVRI), confirmed that the same vaccine will be tested in Uganda in a joint effort by the Government of Uganda and the International AIDS Vaccine Initiative (IAVI). The two parties last month signed an agreement to carry out the trials, to be based at UVRI in Entebbe.
While in Kampala last month, IAVI President Dr. Seth Berkley, said the first volunteers in Uganda would receive the DNA vaccine by the beginning of next year.
It is the first vaccine designed for the sub-type of HIV that exists in East Africa.
The vaccine was designed to make the recipient develop immunity in a manner similar to Kenyan prostitutes who continuously had unprotected sex with HIV-infected men but did not have the virus.
When scientists examined their blood, they were found to have BHIV killer cells in their bodies.
010914
NV010910
Copyright © 2001 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .